Applying the 2023 ASCO-CAP guideline updates for HER2 testing in breast cancer
contributed by Daiichi Sankyo and AstraZeneca |
The 2023 ASCO-CAP guideline updates for HER2 testing in breast cancer focused on assessment and reporting practices for HER2-low (HER2 IHC 1+, IHC 2+/ISH-) expression. As HER2-low classification can impact decisions made by the clinical care team, it is important to standardize clinical practice to ensure tumors with low levels of HER2 expression are assessed and reported consistently.
Our latest application note discusses how pathology laboratories can implement the 2023 ASCO-CAP guideline update recommendations in practice, with examples from a pathologist who has already started integrating them into their institution.
Log in or register to gain full unlimited access to all content on the The Pathologist site. It’s FREE!